Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Prepaid Assets (2022 - 2025)

BioXcel Therapeutics has reported Prepaid Assets over the past 4 years, most recently at $4.0 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $4.0 million for Q4 2025, down 23.86% from a year ago — trailing twelve months through Dec 2025 was $4.0 million (down 23.86% YoY), and the annual figure for FY2025 was $4.0 million, down 23.86%.
  • Prepaid Assets for Q4 2025 was $4.0 million at BioXcel Therapeutics, up from $934000.0 in the prior quarter.
  • Over the last five years, Prepaid Assets for BTAI hit a ceiling of $5.5 million in Q3 2022 and a floor of $934000.0 in Q3 2025.
  • Median Prepaid Assets over the past 4 years was $3.5 million (2022), compared with a mean of $3.3 million.
  • Biggest five-year swings in Prepaid Assets: skyrocketed 173.83% in 2023 and later plummeted 64.56% in 2024.
  • BioXcel Therapeutics' Prepaid Assets stood at $3.1 million in 2022, then fell by 9.29% to $2.8 million in 2023, then surged by 90.15% to $5.3 million in 2024, then decreased by 23.86% to $4.0 million in 2025.
  • The last three reported values for Prepaid Assets were $4.0 million (Q4 2025), $934000.0 (Q3 2025), and $995000.0 (Q2 2025) per Business Quant data.